Trifluoroacetic acid → HCID 24896740, compound
Reaction equation
Cl[CH2:2][C:3]([NH:5][C:6]1[CH:19]=[CH:18][C:9]2[O:10][C:11]3[CH2:17][CH2:16][CH2:15][CH2:14][CH2:13][C:12]=3[C:8]=2[CH:7]=1)=[O:4].[O:20]1[C:24]2([CH2:29][CH2:28][NH:27][CH2:26][CH2:25]2)[O:23][CH2:22][CH2:21]1.C(=O)([O-])[O-].[Cs+].[Cs+].FC(F)(F)C(O)=O>C(#N)C>[O:20]1[C:24]2([CH2:29][CH2:28][N:27]([CH2:2][C:3]([NH:5][C:6]3[CH:19]=[CH:18][C:9]4[O:10][C:11]5[CH2:17][CH2:16][CH2:15][CH2:14][CH2:13][C:12]=5[C:8]=4[CH:7]=3)=[O:4])[CH2:26][CH2:25]2)[O:23][CH2:22][CH2:21]1Participants
6
Procedure
Following the procedure of Example 40, 2-chloro-N-7,8,9,10-tetrahydro-6H-benzo[b]cyclohepta[d]furan-2-ylacetamide (0.13 g, 0.45 mmol), 1,4-dioxa-8-azaspiro(4.5)decane (0.072 mL, 0.56 mmol), and cesium carbonate (0.29 g, 0.90 mmol) in acetonitrile (5 mL) provided 2-(1,4-dioxa-8-azaspiro[4.5]dec-8-yl)-N-7,8,9,10-tetrahydro-6H-benzo[b]cyclohepta[d]furan-2-ylacetamide (0.080 g) as its trifluroacetic acid salt after reverse-phase HPLC purification.MS (ESI) m/z 385 ([M+H]+).
Sources & evidence
- ORD record
- ord-089fc6a7480d43fd8838b56ffbf66915
- Source dataset
- uspto-grants-2009_10
- Patent number
- US07601856B2
Reaction notes
Loading…